Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec 18:7:11-7.
doi: 10.2147/CCID.S51938. eCollection 2014.

Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports

Sebastian Torres  1 , Mark Hamilton  2 , Elena Sanches  3 , Polina Starovatova  4 , Elena Gubanova  4 , Tatiana Reshetnikova  5
Affiliations

Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports

Sebastian Torres et al. Clin Cosmet Investig Dermatol. .

Abstract

Botulinum neurotoxin injections are a valuable treatment modality for many therapeutic indications as well as in the aesthetic field for facial rejuvenation. As successful treatment requires repeated injections over a long period of time, secondary resistance to botulinum toxin preparations after repeated injections is an ongoing concern. We report five case studies in which neutralizing antibodies to botulinum toxin type A developed after injection for aesthetic use and resulted in secondary treatment failure. These results add to the growing number of reports in the literature for secondary treatment failure associated with high titers of neutralizing antibodies in the aesthetic field. Clinicians should be aware of this risk and implement injection protocols that minimize resistance development.

Keywords: aesthetic medicine; botulinum neurotoxin type A; neutralizing antibody; secondary treatment failure.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Case 1: pretreatment photos.
Figure 2
Figure 2
Case 1: 2 weeks posttreatment photos.
Figure 3
Figure 3
Case 2: pretreatment photos.
Figure 4
Figure 4
Case 2: 2 weeks posttreatment photo.
See this image and copyright information in PMC

References

    1. 15thAnnual Cosmetic Surgery National Data Bank Statistics. New York, NY: The American Society for Aesthetic Plastic Surgery (ASAPS); 2012. [Accessed. September 30, 2013]. Available from: http://www.surgery.org/sites/default/files/ASAPS-2011-Stats.pdf.
    1. Total Procedures For Top 25 Countries. International Society of Aesthetic Plastic Surgeons; 2009. [Accessed Sep 2012]. Available from: http://www.isaps.org/files/html-contents/Raw_data_Survey2009.pdf.
    1. Göschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies – therapeutic consequences. Exp Neurol. 1997;147:96–102. - PubMed
    1. Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord. 2004;19(Suppl 8):S92–S100. - PubMed
    1. Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics. 2010;4:325–332. - PMC - PubMed

LinkOut - more resources